<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Diabetes Res</journal-id><journal-id journal-id-type="publisher-id">EDR</journal-id><journal-title>Experimental Diabetes Research</journal-title><issn pub-type="ppub">1687-5214</issn><issn pub-type="epub">1687-5303</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1155/2008/730594</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>C-Peptide and Its C-Terminal Fragments Improve Erythrocyte Deformability in Type 1 Diabetes Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hach</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I1"><sup>1,2</sup></xref><xref ref-type="aff" rid="I2"/><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Forst</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I1"><sup>1,3</sup></xref><xref ref-type="aff" rid="I3"/></contrib><contrib contrib-type="author"><name><surname>Kunt</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ekberg</surname><given-names>Karin</given-names></name><xref ref-type="aff" rid="I5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pf&#x000fc;tzner</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wahren</surname><given-names>John</given-names></name><xref ref-type="aff" rid="I5"><sup>5</sup></xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Department of Internal Medicine, University of Mainz, 55101 Mainz, Germany</aff><aff id="I2"><sup>2</sup>McKinsey &#x00026; Company, Inc., Am Sandtorkai 77, 20457 Hamburg, Germany</aff><aff id="I3"><sup>3</sup>Institute for Clinical Research and Development, 55116 Mainz, Germany</aff><aff id="I4"><sup>4</sup>Department of Internal Medicine, Zayed Military Hospital, P.O. Box 3740, Abu Dhabi, United Arab Emirates</aff><aff id="I5"><sup>5</sup>Department of Molecular Medicine and Surgery, Section of Clinical Physiology, Karolinska Institute, 17177 Stockholm, Sweden</aff><author-notes><corresp id="cor1">*Thomas Hach: <email>thomas_ hach@mckinsey.com</email></corresp><fn><p>Recommended by Subrata Chakrabarti</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>6</day><month>5</month><year>2008</year></pub-date><volume>2008</volume><elocation-id>730594</elocation-id><history><date date-type="received"><day>9</day><month>10</month><year>2007</year></date><date date-type="accepted"><day>27</day><month>2</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Thomas Hach et al.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p><italic>Aims/hypothesis</italic>. Data now indicate that proinsulin C-peptide exerts important physiological effects and shows the characteristics of an endogenous peptide hormone. This study aimed to investigate the influence of C-peptide and fragments thereof on erythrocyte deformability and to elucidate the relevant signal transduction pathway. <italic>Methods</italic>. Blood samples from 23 patients with type 1 diabetes and 15 matched healthy controls were incubated with 6.6 nM of either human C-peptide, C-terminal hexapeptide, C-terminal pentapeptide, a middle fragment comprising residues 11&#x02013;19 of C-peptide, or randomly scrambled C-peptide. Furthermore, red blood cells from 7 patients were incubated with C-peptide, penta- and hexapeptides with/without addition of ouabain, EDTA, or pertussis toxin. Erythrocyte deformability was measured using a laser diffractoscope in the shear stress range 0.3&#x02013;60 Pa. <italic>Results</italic>. Erythrocyte deformability was impaired by 18&#x02013;25% in type 1 diabetic patients compared to matched controls in the physiological shear stress range 0.6&#x02013;12 Pa (<italic>P</italic> &#x0003c; .01&#x02013;.001). C-peptide, penta- and hexapeptide all significantly improved the impaired erythrocyte deformability of type 1 diabetic patients, while the middle fragment and scrambled C-peptide had no detectable effect. Treatment of erythrocytes with ouabain or EDTA completely abolished the C-peptide, penta- and hexapeptide effects. Pertussis toxin in itself significantly increased erythrocyte deformability. <italic>Conclusion/interpretation</italic>. C-peptide and its C-terminal fragments are equally effective in improving erythrocyte deformability in type 1 diabetes. The C-terminal residues of C-peptide are causally involved in this effect. The signal transduction pathway is Ca<sup>2+</sup>-dependent and involves activation of red blood cell Na<sup>+</sup>, K<sup>+</sup>-ATPase.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. INTRODUCTION</title><p>During the past decade, several studies have provided evidence that C-peptide is a biologically active endogenous peptide. It binds specifically in nanomolar concentration to cell membranes [<xref ref-type="bibr" rid="B1">1</xref>], possibly to a G-protein-coupled receptor, resulting in internalisation of the peptide [<xref ref-type="bibr" rid="B2">2</xref>] and activation of Ca<sup>2+</sup>- and MAPK-dependent signalling pathways [<xref ref-type="bibr" rid="B3">3</xref>&#x02013;<xref ref-type="bibr" rid="B6">6</xref>]. Cellular end-effects include stimulation and induction of both Na<sup>+</sup>, K<sup>+</sup>-ATPase, and eNOS as well as activation of a series of transcriptional fators [<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B7">7</xref>&#x02013;<xref ref-type="bibr" rid="B10">10</xref>]. Studies in patients with type 1 diabetes who lack endogenous C-peptide production show that administration of C-peptide in replacement doses results in increased regional blood flow in several tissues [<xref ref-type="bibr" rid="B11">11</xref>&#x02013;<xref ref-type="bibr" rid="B13">13</xref>] and amelioration of diabetes-induced functional and structural abnormalities of the peripheral nerves and the kidneys [<xref ref-type="bibr" rid="B14">14</xref>&#x02013;<xref ref-type="bibr" rid="B16">16</xref>]. Not only the full-length native C-peptide but also its C-terminal pentapeptide fragment is reported to exert physiological effects [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>].</p><p>It is well established that diabetes is associated with reduced deformability of red blood cells [<xref ref-type="bibr" rid="B19">19</xref>&#x02013;<xref ref-type="bibr" rid="B21">21</xref>]. This abnormality is of clinical significance in that it compromises the ability of red blood cells to pass through capillaries, reduces tissue perfusion, and impairs tissue oxygen supply [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B22">22</xref>]. The mechanism underlying the decreased red cell compliance in diabetes is not well understood, but it has been shown that C-peptide is capable of restoring red cell deformability to normal levels, most likely via stimulation of red cell Na<sup>+</sup>, K<sup>+</sup>-ATPase [<xref ref-type="bibr" rid="B23">23</xref>]. The extent to which C-peptide fragments will do the same has not been determined. Consequently, the aim of this study was to examine the influence of C-peptide and its C-terminal fragments, as well as middle segments on the abnormal deformability of red blood cells from type 1 diabetes patients. In addition, aspects of a possible signal transduction pathway were evaluated.</p></sec><sec sec-type="section" id="sec2"><title>2. SUBJECTS, MATERIALS, AND METHODS</title><sec sec-type="subsection" id="subsec2.1"><title>2.1. Subjects</title><p> Blood samples were taken from 23 type 1 diabetes patients and 15 matched healthy controls (<xref ref-type="table" rid="tab1">Table 1</xref>). Inclusion criteria were C-peptide serum level &#x0003c; 0.2 nmol/L, diabetes duration &#x0003e; 2 years, serum creatinine &#x0003c; 2 mg/dL, and no clinically relevant diabetic long-term complications. Hematocrit values were in the normal range for all patients and controls.</p></sec><sec sec-type="subsection" id="subsec2.2"><title>2.2. Materials and methods</title><p> Laser diffractoscopy was performed using a Rheodyn SSD shear stress diffractometer (Myrenne GmbH, Roetgen, Germany). The method of laser diffractoscopy has been described in detail previously [<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B23">23</xref>]. In summary, a He-Ne-Laser detects deformation of erythrocytes between two parallel glass discs, one of which rotates resulting in defined shear stresses as per the following equation: <disp-formula id="eq1"><label>(1)</label><mml:math id="M1"><mml:mrow><mml:mi>&#x003c4;</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mi>&#x003c0;</mml:mi><mml:mi>r</mml:mi><mml:mo>&#x022c5;</mml:mo><mml:mi>&#x003b7;</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>&#x022c5;</mml:mo><mml:mi>h</mml:mi></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula> where <italic>&#x003c4;</italic> = shear stress, <italic>r</italic> = laser beam distance from rotation center, <italic>&#x003b7;</italic> = viscosity, <italic>h</italic> = height of gap between discs, and <italic>t</italic> = time.</p><p>Adjusting for equipment-specific values (<italic>r</italic> = 25 mm, <italic>h</italic> = 0.5 mm, and <italic>&#x003b7;</italic> = 24 mPa), the equation is condensed to <disp-formula id="eq2"><label>(2)</label><mml:math id="M2"><mml:mrow><mml:mi>&#x003c4;</mml:mi><mml:mo>=</mml:mo><mml:mn>7.536</mml:mn><mml:mtext></mml:mtext><mml:mtext>Pa</mml:mtext><mml:mo>&#x022c5;</mml:mo><mml:mtext>rpm</mml:mtext><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula> where rpm = revolutions per minute.</p><p>The applied shear stress range is electronically regulated and includes 8 levels (0.3 Pa; 0.6 Pa; 1.2 Pa; 3 Pa; 6 Pa; 12 Pa; 30 Pa; 60 Pa).</p><p>The erythrocyte deformability measurement detects scattered-light intensities along orthogonal axes (A, B) of red blood cells within the laser diffraction light cone. The erythrocyte elongation index (EI) is calculated by the following equation:</p><disp-formula id="aa3"><label>(3)</label><mml:math id="M3"><mml:mrow><mml:mtext>EI</mml:mtext><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mo>%</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mrow><mml:mtext>A</mml:mtext><mml:mo>&#x02212;</mml:mo><mml:mtext>B</mml:mtext></mml:mrow><mml:mrow><mml:mtext>A</mml:mtext><mml:mo>+</mml:mo><mml:mtext>B</mml:mtext></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo><mml:mo>&#x022c5;</mml:mo><mml:mn>100.</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula><p>All experiments were carried out at 23&#x000b0;C, which was thermostatically regulated. Blood samples were collected using ammonium-heparinated vials and subsequently distributed to dextran medium (30 <italic>&#x003bc;</italic>L blood per 2 mL dextran). Stability tests were performed to exclude significant effects of storage time and/or serum glucose concentration on erythrocyte deformability measured by laser diffractoscopy (data not shown). All measurements of erythrocyte deformability were carried out before incubation with active ingredients as well as at 1, 30, and 60 minutes after incubation</p><p><statement><title>C-peptide and C-peptide fragments</title><p> Human C-peptide and all C-peptide fragments were provided by Creative Peptides (Stockholm, Sweden) at a purity of &#x0003e;98%. C-peptide and its fragments were dissolved in phosphate buffer and incubations were made at 6.6 nmol/L. The incubation and mixing of probes were done smoothly to avoid external shear stress. The fragments used in this study were C-terminal hexapeptide, C-terminal pentapeptide, a middle fragment including residues 11&#x02013;19, and randomly scrambled C-peptide; their amino acid sequences are presented in <xref ref-type="table" rid="tab2">Table 2</xref>.</p></statement></p><p><statement><title>Ouabain</title><p> Ouabain was obtained from Sigma-Aldrich (St. Louis, Mo, USA). Treatment with ouabain was titrated to achieve a concentration of 1 <italic>&#x003bc;</italic>mol/L. Incubations with and without C-peptide or fragments lasted 30 minutes at 23&#x000b0;C.</p></statement></p><p><statement><title>EDTA</title><p> Incubations with EDTA (1.6 mg/mL) with and without C-peptide or fragments lasted 30 minutes at 23&#x000b0;C. Treatment with EDTA alone did not alter erythrocyte deformability (data not shown).</p></statement></p><p><statement><title>Pertussis toxin</title><p> Pertussis toxin was obtained from Sigma-Aldrich. Treatment with pertussis toxin (1 <italic>&#x003bc;</italic>g/mL) was conducted for 60 minutes at 37&#x000b0;C.</p></statement></p><p><statement><title>Statistical analysis</title><p> Results are expressed as the means &#x000b1; SD. Gaussian distribution was checked by the Kolmogoroff-Smirnoff test. Statistical analysis were done by two-site ANOVA and Student's <italic>t</italic> test. A <italic>P</italic>-value of less than .05 was regarded as statistically significant.</p></statement></p></sec></sec><sec sec-type="section" id="sec3"><title>3. RESULTS</title><p>Erythrocyte deformability was significantly decreased in type 1 diabetes patients compared to healthy controls over the full range of shear stress tested (<xref ref-type="fig" rid="fig1">Figure 1</xref>). In the physiological shear stress range (&#x02264;12 Pa), the difference between diabetic patients and healthy controls amounted to 18&#x02013;25% (<italic>P</italic> &#x0003c; .01&#x02013;.001) Incubation of the red cells from type 1 diabetes patients with C-peptide completely normalized the erythrocyte defortmability at all tested shear stress levels (<xref ref-type="table" rid="tab3">Table 3</xref>). Incubation with the penta- and hexapeptides also resulted in significant improvements in erythrocyte deformability over the range of shear stress tested; the responses to C-peptide and the C-terminal peptides were similar and there were no statistically significant differences between these three treatment groups. In contrast, the middle fragment exerted no significant effect on the diabetes-induced abnormal erythrocyte deformability. Likewise and as expected, scrambled C-peptide with a random amino acid sequence had no beneficial effect on erythrocyte deformability.</p><p>Pretreatment of erythrocytes from patients with type 1 diabetes with ouabain or EDTA completely abolished the C-peptide-, penta- and hexapeptide-induced improvements in deformability as shown in <xref ref-type="fig" rid="fig2">Figure 2</xref> for the pentapeptide at the shear stress 1.2 Pa. Similar results were obtained for all levels of shear stress. Pretreatment of erythrocytes with pertussis toxin in itself increased erythrocyte deformability significantly (<italic>P</italic> &#x0003c; .05) in the shear stress range of 0.6&#x02013;12 Pa. Therefore, the possible influence of G-protein inactivation on the effects mediated by C-peptide and its fragments could not be evaluated.</p></sec><sec sec-type="section" id="sec4"><title>4. DISCUSSION</title><p>The present results confirm and extend previous observations indicating that red blood cell deformability is compromised in diabetes [<xref ref-type="bibr" rid="B19">19</xref>&#x02013;<xref ref-type="bibr" rid="B21">21</xref>] and that this abnormality can be corrected by C-peptide [<xref ref-type="bibr" rid="B23">23</xref>]. Thus, using whole blood samples and laser diffractoscopy, a method with high reproducibility (CV &#x0003c; 1%), erythrocyte deformability measured in blood samples from type 1 diabetes patients was found to be reduced by 18&#x02013;25% over the physiological shear stress range (0.6&#x02013;12 Pa), in keeping with previous results using the same methodology [<xref ref-type="bibr" rid="B23">23</xref>]. Exposing blood cells from the diabetic patients to 6.6 nM, C-peptide was found to fully normalize membrane deformability. We now show that not only the native, full length C-peptide but also its C-terminal penta- and hexapeptides possess this capability. In contrast, a middle segment comprising residues 11&#x02013;19 of C-peptide had no effect. The specificity of the observed effects is attested by the finding that scrambled C-peptide, a control peptide with its residues assembled in random order, had no detectable effect.</p><p>The current results for the pentapeptide are in line with previous reports that it competes with C-peptide for cellular binding [<xref ref-type="bibr" rid="B1">1</xref>], that it elicits an increase in intracellular Ca<sup>2+</sup>-concentration [<xref ref-type="bibr" rid="B4">4</xref>], activates PKC isoforms, causes phosphorylation of ERK1/2 and JNK, and stimulates Na<sup>+</sup>, K<sup>+</sup>-ATPase activity [<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B24">24</xref>]. Studies evaluating the pentapeptide's cellular binding/competition characteristics, its stimulatory effect on intracellular Ca<sup>2+</sup>-concentrations and ERK1/2 phosphorylation demonstrate that it is the N-terminal Glu-residue of the pentapeptide (Glu 27 of C-peptide) that is of primary importance for its bioactivity; alanine substitution of the other four residues has little or no effect on the pentapeptide's bioactivity [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B26">26</xref>]. Its bioactivity has been found to be similar to that of the native peptide both in the above in vitro studies and in invivo experiments evaluating its stimulatory effect on whole-body glucose utilization [<xref ref-type="bibr" rid="B18">18</xref>] and its inhibition of diabetes-induced glomerular hyperfiltration [<xref ref-type="bibr" rid="B27">27</xref>] in streptozotocin-diabetic rats.</p><p>The C-terminal hexapeptide was found to be equally potent as the pentapeptide and the native C-peptide with regard to its amelioration of diabetes-induced abnormal red blood cell deformability (<xref ref-type="fig" rid="fig2">Figure 2</xref>). Only little information is available with regard to the physiology of the hexapeptide but the current findings are in line with previous observations that it is capable of stimulating Na<sup>+</sup>, K<sup>+</sup>-ATPase in renal tubular segments with potency similar to that of the pentapeptide [<xref ref-type="bibr" rid="B17">17</xref>]. In contrast to the findings for the two C-terminal segments, there was no indication that the middle fragment (residues 11&#x02013;19) exerted a measurable effect on diabetes-induced abnormal red cell deformability. Variable results have been reported previously for middle fragments; mild stimulation of Na<sup>+</sup>, K<sup>+</sup>-ATPase in renal tubule segments [<xref ref-type="bibr" rid="B17">17</xref>] but no effect on glucose utilization under in vivo conditions [<xref ref-type="bibr" rid="B18">18</xref>] have been observed.</p><p>Exposing red blood cells from patients with type 1 diabetes to either oubain or EDTA resulted in complete abrogation of the normalizing effect by the penta- and hexapeptides or C-peptide on erythrocyte deformability. Evaluation of a G-protein involvement in the signalling pathway could not be carried out since exposure of the erythrocytes to pertussis toxin in itself resulted in alteration of red cell deformability in contrast to previous findings for rabbit erythrocytes [<xref ref-type="bibr" rid="B28">28</xref>]. Nevertheless, the results indicate that the beneficial effects of the peptides are mediated via a Ca<sup>2+</sup>-dependent stimulation of erythrocyte Na<sup>+</sup>, K<sup>+</sup>-ATPase, in analogy with the previously established signal transduction pathway for C-peptide and Na<sup>+</sup>, K<sup>+</sup>-ATPase in human renal tubular cells [<xref ref-type="bibr" rid="B24">24</xref>], even though the EDTA results may suggest that other metal ions also are of importance for the signal transduction [<xref ref-type="bibr" rid="B29">29</xref>].</p><p>Exposure of erythrocytes to C-peptide and its C-terminal fragments is thus likely to result in augmented generation and release of ATP, as has been observed directly in the case of C-peptide and both normal and diabetic red blood cells [<xref ref-type="bibr" rid="B29">29</xref>]. ATP is a recognized stimulus of nitric oxide synthase of platelets and erythrocytes [<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>]. Nitric oxide, besides being a potent vasodilator, is also effective in eliciting improved red blood cell deformability as a result of direct action of nitric oxide on the erythrocyte membrane [<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>]. In addition, C-peptide-related improvement of red cell deformability may be mediated not via ATP but by direct stimulation of red cell nitric oxide synthase. The latter is functionally similar to that of endothelial cells [<xref ref-type="bibr" rid="B31">31</xref>], and C-peptide and most likely also its C-terminal fragments are known to stimulate and cause induction of endothelial nitric oxide synthase [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B10">10</xref>]. The above mechanisms are likely to contribute to the maintenance of normal erythrocyte membrane plasticity and the extent to which they are modified in diabetes is unknown. However, irrespective of the exact mechanism involved, the present findings demonstrate that both C-peptide and its C-terminal fragments are capable of effectively normalizing the diabetes-induced reduction in red blood cell deformability. It is probable that this effect contributed importantly to the observed improvement in regional blood flow of skin, muscle, myocardium, and peripheral nerve in animals and type 1 diabetes patients, following administration of C-peptide to physiological concentrations [<xref ref-type="bibr" rid="B11">11</xref>&#x02013;<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B34">34</xref>]. Furthermore, the beneficial clinical effects of C-peptide on early-stage neuropathy [<xref ref-type="bibr" rid="B14">14</xref>] and nephropathy [<xref ref-type="bibr" rid="B15">15</xref>] in type 1 diabetes may in part be related to correction of the abnormal red cell deformability and subsequently improved microcirculation. Further clinical trials are warranted document and define the role of C-peptide and its C-terminal fragments in the treatment and/or prevention of microvascular complications of type 1 diabetes.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rigler</surname><given-names>R</given-names></name><name><surname>Pramanik</surname><given-names>A</given-names></name><name><surname>Jonasson</surname><given-names>P</given-names></name><etal/></person-group><article-title>Specific binding of proinsulin C-peptide to human cell membranes</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1999</year><volume>96</volume><issue>23</issue><fpage>13318</fpage><lpage>13323</lpage><pub-id pub-id-type="pmid">10557318</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lindahl</surname><given-names>E</given-names></name><name><surname>Nyman</surname><given-names>U</given-names></name><name><surname>Melles</surname><given-names>E</given-names></name><etal/></person-group><article-title>Cellular internalization of proinsulin C-peptide</article-title><source><italic>Cellular and Molecular Life Sciences</italic></source><year>2007</year><volume>64</volume><issue>4</issue><fpage>479</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">17279313</pub-id></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohtomo</surname><given-names>Y</given-names></name><name><surname>Aperia</surname><given-names>A</given-names></name><name><surname>Sahlgren</surname><given-names>B</given-names></name><name><surname>Johansson</surname><given-names>B-L</given-names></name><name><surname>Wahren</surname><given-names>J</given-names></name></person-group><article-title>C-peptide stimulates rat renal tubular Na<sup>+</sup>, K<sup>+</sup>-ATPase activity in synergism with neuropeptide Y</article-title><source><italic>Diabetologia</italic></source><year>1996</year><volume>39</volume><issue>2</issue><fpage>199</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">8635672</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shafqat</surname><given-names>J</given-names></name><name><surname>Juntti-Berggren</surname><given-names>L</given-names></name><name><surname>Zhong</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Proinsulin C-peptide and its analogues induce intracellular Ca<sup>2+</sup> increases in human renal tubular cells</article-title><source><italic>Cellular and Molecular Life Sciences</italic></source><year>2002</year><volume>59</volume><issue>7</issue><fpage>1185</fpage><lpage>1189</lpage><pub-id pub-id-type="pmid">12222964</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kitamura</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Jung</surname><given-names>BD</given-names></name><etal/></person-group><article-title>Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein</article-title><source><italic>Biochemical Journal</italic></source><year>2001</year><volume>355</volume><issue>1</issue><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">11256956</pub-id></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>Z</given-names></name><name><surname>Davidescu</surname><given-names>A</given-names></name><name><surname>Ehr&#x000e9;n</surname><given-names>I</given-names></name><etal/></person-group><article-title>C-peptide stimulates ERK1/2 and JNK MAP kinases via activation of protein kinase C in human renal tubular cells</article-title><source><italic>Diabetologia</italic></source><year>2005</year><volume>48</volume><issue>1</issue><fpage>187</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">15624099</pub-id></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsimaratos</surname><given-names>M</given-names></name><name><surname>Roger</surname><given-names>F</given-names></name><name><surname>Chabard&#x000e8;s</surname><given-names>D</given-names></name><etal/></person-group><article-title>C-peptide stimulates Na<sup>+</sup>, K<sup>+</sup>-ATPase activity via PKC alpha in rat medullary thick ascending limb</article-title><source><italic>Diabetologia</italic></source><year>2003</year><volume>46</volume><issue>1</issue><fpage>124</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">12637991</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wallerath</surname><given-names>T</given-names></name><name><surname>Kunt</surname><given-names>T</given-names></name><name><surname>Forst</surname><given-names>T</given-names></name><etal/></person-group><article-title>Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide</article-title><source><italic>Nitric Oxide</italic></source><year>2003</year><volume>9</volume><issue>2</issue><fpage>95</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">14623175</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scalia</surname><given-names>R</given-names></name><name><surname>Coyle</surname><given-names>KM</given-names></name><name><surname>Levine</surname><given-names>BJ</given-names></name><name><surname>Booth</surname><given-names>G</given-names></name><name><surname>Lefer</surname><given-names>AM</given-names></name></person-group><article-title>C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction</article-title><source><italic>The FASEB Journal</italic></source><year>2000</year><volume>14</volume><issue>14</issue><fpage>2357</fpage><lpage>2364</lpage><pub-id pub-id-type="pmid">11053258</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kitamura</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>K</given-names></name><name><surname>Makondo</surname><given-names>K</given-names></name><etal/></person-group><article-title>Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats</article-title><source><italic>Diabetologia</italic></source><year>2003</year><volume>46</volume><issue>12</issue><fpage>1698</fpage><lpage>1705</lpage><pub-id pub-id-type="pmid">14586499</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Forst</surname><given-names>T</given-names></name><name><surname>Kunt</surname><given-names>T</given-names></name><name><surname>Pohlmann</surname><given-names>T</given-names></name><etal/></person-group><article-title>Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus</article-title><source><italic>Journal of Clinical Investigation</italic></source><year>1998</year><volume>101</volume><issue>10</issue><fpage>2036</fpage><lpage>2041</lpage><pub-id pub-id-type="pmid">9593759</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>B-L</given-names></name><name><surname>Linde</surname><given-names>B</given-names></name><name><surname>Wahren</surname><given-names>J</given-names></name></person-group><article-title>Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients</article-title><source><italic>Diabetologia</italic></source><year>1992</year><volume>35</volume><issue>12</issue><fpage>1151</fpage><lpage>1158</lpage><pub-id pub-id-type="pmid">1478367</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cotter</surname><given-names>MA</given-names></name><name><surname>Ekberg</surname><given-names>K</given-names></name><name><surname>Wahren</surname><given-names>J</given-names></name><name><surname>Cameron</surname><given-names>NE</given-names></name></person-group><article-title>Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition</article-title><source><italic>Diabetes</italic></source><year>2003</year><volume>52</volume><issue>7</issue><fpage>1812</fpage><lpage>1817</lpage><pub-id pub-id-type="pmid">12829651</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ekberg</surname><given-names>K</given-names></name><name><surname>Brismar</surname><given-names>T</given-names></name><name><surname>Johansson</surname><given-names>B-L</given-names></name><etal/></person-group><article-title>C-peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy</article-title><source><italic>Diabetes Care</italic></source><year>2007</year><volume>30</volume><issue>1</issue><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">17192336</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>B-L</given-names></name><name><surname>Borg</surname><given-names>K</given-names></name><name><surname>Fernqvist-Forbes</surname><given-names>E</given-names></name><name><surname>Kernell</surname><given-names>A</given-names></name><name><surname>Odergren</surname><given-names>T</given-names></name><name><surname>Wahren</surname><given-names>J</given-names></name></person-group><article-title>Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes mellitus</article-title><source><italic>Diabetic Medicine</italic></source><year>2000</year><volume>17</volume><issue>3</issue><fpage>181</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">10784221</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sima</surname><given-names>AAF</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Sugimoto</surname><given-names>K</given-names></name><etal/></person-group><article-title>C-peptide prevents and improves chronic type I diabetic polyneuropathy in the BB/Wor rat</article-title><source><italic>Diabetologia</italic></source><year>2001</year><volume>44</volume><issue>7</issue><fpage>889</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">11508275</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohtomo</surname><given-names>Y</given-names></name><name><surname>Bergman</surname><given-names>T</given-names></name><name><surname>Johansson</surname><given-names>B-L</given-names></name><name><surname>J&#x000f6;rnvall</surname><given-names>H</given-names></name><name><surname>Wahren</surname><given-names>J</given-names></name></person-group><article-title>Differential effects of proinsulin C-peptide fragments on Na<sup>+</sup>, K<sup>+</sup>-ATPase activity of renal tubule segments</article-title><source><italic>Diabetologia</italic></source><year>1998</year><volume>41</volume><issue>3</issue><fpage>287</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">9541168</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Oshida</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>Y-Q</given-names></name><etal/></person-group><article-title>C-peptide fragments stimulate glucose utilization in diabetic rats</article-title><source><italic>Cellular and Molecular Life Sciences</italic></source><year>2004</year><volume>61</volume><issue>6</issue><fpage>727</fpage><lpage>732</lpage><pub-id pub-id-type="pmid">15052415</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>CD</given-names></name><name><surname>Ghali</surname><given-names>HS</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Thomas</surname><given-names>LL</given-names></name><name><surname>Friedman</surname><given-names>EA</given-names></name></person-group><article-title>Association of reduced red blood cell deformability and diabetic nephropathy</article-title><source><italic>Kidney International</italic></source><year>2005</year><volume>67</volume><issue>1</issue><fpage>295</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">15610255</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garnier</surname><given-names>M</given-names></name><name><surname>Attali</surname><given-names>JR</given-names></name><name><surname>Valensi</surname><given-names>P</given-names></name><name><surname>Delatour-Hanss</surname><given-names>E</given-names></name><name><surname>Gaudey</surname><given-names>F</given-names></name><name><surname>Koutsouris</surname><given-names>D</given-names></name></person-group><article-title>Erythrocyte deformability in diabetes and erythrocyte membrane lipid composition</article-title><source><italic>Metabolism</italic></source><year>1990</year><volume>39</volume><issue>8</issue><fpage>794</fpage><lpage>798</lpage><pub-id pub-id-type="pmid">2377077</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmid-Schoenbein</surname><given-names>H</given-names></name><name><surname>Volger</surname><given-names>E</given-names></name></person-group><article-title>Red cell aggregation and red cell deformability in diabetes</article-title><source><italic>Diabetes</italic></source><year>1976</year><volume>25, supplement 2</volume><fpage>897</fpage><lpage>902</lpage><pub-id pub-id-type="pmid">971793</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parthasarathi</surname><given-names>K</given-names></name><name><surname>Lipowsky</surname><given-names>HH</given-names></name></person-group><article-title>Capillary recruitment in response to tissue hypoxia and its dependence on red blood cell deformability</article-title><source><italic>American Journal of Physiology</italic></source><year>1999</year><volume>277</volume><issue>6</issue><fpage>H2145</fpage><lpage>H2157</lpage><pub-id pub-id-type="pmid">10600832</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kunt</surname><given-names>T</given-names></name><name><surname>Schneider</surname><given-names>S</given-names></name><name><surname>Pf&#x000fc;tzner</surname><given-names>A</given-names></name><etal/></person-group><article-title>The effect of human proinsulin C-peptide on erythrocyte deformability in patients with type I diabetes mellitus</article-title><source><italic>Diabetologia</italic></source><year>1999</year><volume>42</volume><issue>4</issue><fpage>465</fpage><lpage>471</lpage><pub-id pub-id-type="pmid">10230651</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>Z</given-names></name><name><surname>Kotova</surname><given-names>O</given-names></name><name><surname>Davidescu</surname><given-names>A</given-names></name><etal/></person-group><article-title>C-peptide stimulates Na<sup>+</sup>, K<sup>+</sup>-ATPase via activation of ERK1/2 MAP kinases in human renal tubular cells</article-title><source><italic>Cellular and Molecular Life Sciences</italic></source><year>2004</year><volume>61</volume><issue>21</issue><fpage>2782</fpage><lpage>2790</lpage><pub-id pub-id-type="pmid">15549182</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pramanik</surname><given-names>A</given-names></name><name><surname>Ekberg</surname><given-names>K</given-names></name><name><surname>Zhong</surname><given-names>Z</given-names></name><etal/></person-group><article-title>C-peptide binding to human cell membranes: importance of Glu27</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>2001</year><volume>284</volume><issue>1</issue><fpage>94</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">11374876</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Henriksson</surname><given-names>M</given-names></name><name><surname>Nordling</surname><given-names>E</given-names></name><name><surname>Melles</surname><given-names>E</given-names></name><etal/></person-group><article-title>Separate functional features of proinsulin C-peptide</article-title><source><italic>Cellular and Molecular Life Sciences</italic></source><year>2005</year><volume>62</volume><issue>15</issue><fpage>1772</fpage><lpage>1778</lpage><pub-id pub-id-type="pmid">16003487</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nordquist</surname><given-names>L</given-names></name><name><surname>Moe</surname><given-names>E</given-names></name><name><surname>Sj&#x000f6;quist</surname><given-names>M</given-names></name></person-group><article-title>The C-peptide fragment EVARQ reduces glomerular hyperfiltration in streptozotocin-induced diabetic rats</article-title><source><italic>Diabetes/Metabolism Research and Reviews</italic></source><year>2007</year><volume>23</volume><issue>5</issue><fpage>400</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">17103462</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Olearczyk</surname><given-names>JJ</given-names></name><name><surname>Stephenson</surname><given-names>AH</given-names></name><name><surname>Lonigro</surname><given-names>AJ</given-names></name><name><surname>Sprague</surname><given-names>RS</given-names></name></person-group><article-title>Heterotrimeric G protein G<sub>i</sub> is involved in a signal transduction pathway for ATP release from erythrocytes</article-title><source><italic>American Journal of Physiology</italic></source><year>2004</year><volume>286</volume><issue>3</issue><fpage>H940</fpage><lpage>H945</lpage><pub-id pub-id-type="pmid">14615280</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>JA</given-names></name><name><surname>Froelich</surname><given-names>JM</given-names></name><name><surname>Reid</surname><given-names>GE</given-names></name><name><surname>Karunarathne</surname><given-names>WKA</given-names></name><name><surname>Spence</surname><given-names>DM</given-names></name></person-group><article-title>Metal-activated C-peptide facilitates glucose clearance and the release of a nitric oxide stimulus via the GLUT1 transporter</article-title><source><italic>Diabetologia</italic></source><year>2008</year><volume>51</volume><issue>1</issue><fpage>175</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">17965850</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carroll</surname><given-names>JS</given-names></name><name><surname>Ku</surname><given-names>C-J</given-names></name><name><surname>Karunarathne</surname><given-names>W</given-names></name><name><surname>Spence</surname><given-names>DM</given-names></name></person-group><article-title>Red blood cell stimulation of platelet nitric oxide production indicated by quantitative monitoring of the communication between cells in the bloodstream</article-title><source><italic>Analytical Chemistry</italic></source><year>2007</year><volume>79</volume><issue>14</issue><fpage>5133</fpage><lpage>5138</lpage><pub-id pub-id-type="pmid">17580956</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kleinbongard</surname><given-names>P</given-names></name><name><surname>Schulz</surname><given-names>R</given-names></name><name><surname>Rassaf</surname><given-names>T</given-names></name><etal/></person-group><article-title>Red blood cells express a functional endothelial nitric oxide synthase</article-title><source><italic>Blood</italic></source><year>2006</year><volume>107</volume><issue>7</issue><fpage>2943</fpage><lpage>2951</lpage><pub-id pub-id-type="pmid">16368881</pub-id></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Starzyk</surname><given-names>D</given-names></name><name><surname>Korbut</surname><given-names>R</given-names></name><name><surname>Gryglewski</surname><given-names>RJ</given-names></name></person-group><article-title>Effects of nitric oxide and prostacyclin on deformability and aggregability of red blood cells of rats ex vivo and in vitro</article-title><source><italic>Journal of Physiology and Pharmacology</italic></source><year>1999</year><volume>50</volume><issue>4</issue><fpage>629</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">10639013</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bor-Kucukatay</surname><given-names>M</given-names></name><name><surname>Wenby</surname><given-names>RB</given-names></name><name><surname>Meiselman</surname><given-names>HJ</given-names></name><name><surname>Baskurt</surname><given-names>OK</given-names></name></person-group><article-title>Effects of nitric oxide on red blood cell deformability</article-title><source><italic>American Journal of Physiology</italic></source><year>2003</year><volume>284</volume><issue>5</issue><fpage>H1577</fpage><lpage>H1584</lpage><pub-id pub-id-type="pmid">12521942</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>B-L</given-names></name><name><surname>Sundell</surname><given-names>J</given-names></name><name><surname>Ekberg</surname><given-names>K</given-names></name><etal/></person-group><article-title>C-peptide improves adenosine-induced myocardial vasodilation in type 1 diabetes patients</article-title><source><italic>American Journal of Physiology</italic></source><year>2004</year><volume>286</volume><issue>1</issue><fpage>E14</fpage><lpage>E19</lpage><pub-id pub-id-type="pmid">12954595</pub-id></citation></ref></ref-list></back><floats-wrap><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Erythrocyte elongation index (EI) (%) &#x000b1; SD for erythrocytes from healthy controls (open columns) and type 1 diabetes patients (filled columns) at different levels of shear stress. *<italic>P</italic> &#x0003c; .05. **<italic>P</italic> &#x0003c; .01. ***<italic>P</italic> &#x0003c; .001 versus controls.</p></caption><graphic xlink:href="EDR2008-730594.001"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Erythrocyte elongation index <bold>(</bold>EI) (%) &#x000b1; SD for erythrocytes from healthy controls and type 1 diabetes patients. The latter cells were incubated with C-peptide, hexapeptide (HP), and pentapeptide (PP) from the C-terminal region of C-peptide as well as a middle fragment (MF) and scrambled peptide (SCR, control). Results for combined incubation with PP and oubain or EDTA are also shown. Data are obtained at the shear stress level 1.2 Pa. ***<italic>P</italic> &#x0003c; .001 versus untreated erythrocytes from type 1 diabetes patients.</p></caption><graphic xlink:href="EDR2008-730594.002"/></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Clinical characteristics of study subjects.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Healthy controls <italic>n</italic> = 15</th><th align="center" rowspan="1" colspan="1">Type 1 diabetes patients <italic>n</italic> = 23</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Sex (male/female)</td><td align="center" rowspan="1" colspan="1">8/7</td><td align="center" rowspan="1" colspan="1">13/10</td></tr><tr><td rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">34 &#x000b1; 4</td><td align="center" rowspan="1" colspan="1">36 &#x000b1; 3</td></tr><tr><td rowspan="1" colspan="1">Height (m)</td><td align="center" rowspan="1" colspan="1">1.76 &#x000b1; 0.02</td><td align="center" rowspan="1" colspan="1">1.75 &#x000b1; 0.02 </td></tr><tr><td rowspan="1" colspan="1">Weight (kg)</td><td align="center" rowspan="1" colspan="1">78.0 &#x000b1; 2.8</td><td align="center" rowspan="1" colspan="1">77.5 &#x000b1; 2.6</td></tr><tr><td rowspan="1" colspan="1">Diabetes duration (years)</td><td align="center" rowspan="1" colspan="1">0 &#x000b1; 0</td><td align="center" rowspan="1" colspan="1">24 &#x000b1; 3</td></tr><tr><td rowspan="1" colspan="1">Serum glucose (mmol/L)</td><td align="center" rowspan="1" colspan="1">4.94 &#x000b1; 0.22</td><td align="center" rowspan="1" colspan="1">7.44 &#x000b1; 0.67</td></tr><tr><td rowspan="1" colspan="1">HbA1c (%)</td><td align="center" rowspan="1" colspan="1">5.7 &#x000b1; 0.3</td><td align="center" rowspan="1" colspan="1">7.3 &#x000b1; 0.2</td></tr><tr><td rowspan="1" colspan="1">Serum C-peptide (nmol/L)</td><td align="center" rowspan="1" colspan="1">0.77 &#x000b1; 0.09</td><td align="center" rowspan="1" colspan="1">0.01 &#x000b1; 0.003</td></tr></tbody></table></table-wrap><table-wrap id="tab2" position="float"><label>Table 2</label><caption><p>Amino acid structure of C-peptide and C-peptide fragments used in this study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Amino acid structure</th><th align="center" rowspan="1" colspan="1">Position</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">C-Peptide</td><td align="center" rowspan="1" colspan="1">EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ</td><td align="center" rowspan="1" colspan="1">(1&#x02013;31)</td></tr><tr><td rowspan="1" colspan="1">MF</td><td align="center" rowspan="1" colspan="1">ELGGGPGAG</td><td align="center" rowspan="1" colspan="1">(11&#x02013;19)</td></tr><tr><td rowspan="1" colspan="1">HP</td><td align="center" rowspan="1" colspan="1">LEGSLQ</td><td align="center" rowspan="1" colspan="1">(26&#x02013;31)</td></tr><tr><td rowspan="1" colspan="1">PP</td><td align="center" rowspan="1" colspan="1">EGSLQ</td><td align="center" rowspan="1" colspan="1">(27&#x02013;31)</td></tr></tbody></table></table-wrap><table-wrap id="tab3" position="float"><label>Table 3</label><caption><p>Erythrocyte elongation index (EI) (%) in the shear stress range 0.6&#x02013;12 Pa for different treatment groups, <italic>n</italic> = 23.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" colspan="6" rowspan="1">Shear stress</th></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">0.6 Pa</th><th align="center" rowspan="1" colspan="1">1.2 Pa</th><th align="center" rowspan="1" colspan="1">3 Pa</th><th align="center" rowspan="1" colspan="1">6 Pa</th><th align="center" rowspan="1" colspan="1">12 Pa</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Healthy controls</td><td align="center" rowspan="1" colspan="1">5.87 &#x000b1; 0.72*</td><td align="center" rowspan="1" colspan="1">14.37 &#x000b1; 0.61*</td><td align="center" rowspan="1" colspan="1">29.08 &#x000b1; 0.79*</td><td align="center" rowspan="1" colspan="1">39.19 &#x000b1; 1.02*</td><td align="center" rowspan="1" colspan="1">45.93 &#x000b1; 0.85*</td></tr><tr><td rowspan="1" colspan="1">Diabetes patients</td><td align="center" rowspan="1" colspan="1">4.38 &#x000b1; 0.63</td><td align="center" rowspan="1" colspan="1">11.77 &#x000b1; 0.49</td><td align="center" rowspan="1" colspan="1">26.01 &#x000b1; 0.60</td><td align="center" rowspan="1" colspan="1">35.48 &#x000b1; 0.84</td><td align="center" rowspan="1" colspan="1">43.34 &#x000b1; 0.92</td></tr><tr><td rowspan="1" colspan="1">C-peptide</td><td align="center" rowspan="1" colspan="1">5.40 &#x000b1; 0.82*</td><td align="center" rowspan="1" colspan="1">14.11 &#x000b1; 0.85*</td><td align="center" rowspan="1" colspan="1">28.34 &#x000b1; 1.58*</td><td align="center" rowspan="1" colspan="1">39.07 &#x000b1; 1.46*</td><td align="center" rowspan="1" colspan="1">45.82 &#x000b1; 1.43*</td></tr><tr><td rowspan="1" colspan="1">HP</td><td align="center" rowspan="1" colspan="1">5.77 &#x000b1; 0.81*</td><td align="center" rowspan="1" colspan="1">14.18 &#x000b1; 1.17*</td><td align="center" rowspan="1" colspan="1">28.61 &#x000b1; 1.37*</td><td align="center" rowspan="1" colspan="1">38.49 &#x000b1; 1.62*</td><td align="center" rowspan="1" colspan="1">45.82 &#x000b1; 1.81*</td></tr><tr><td rowspan="1" colspan="1">PP</td><td align="center" rowspan="1" colspan="1">6.12 &#x000b1; 0.93*</td><td align="center" rowspan="1" colspan="1">14.02 &#x000b1; 1.37*</td><td align="center" rowspan="1" colspan="1">28.23 &#x000b1; 1.46*</td><td align="center" rowspan="1" colspan="1">38.85 &#x000b1; 1.54*</td><td align="center" rowspan="1" colspan="1">45.20 &#x000b1; 1.74*</td></tr><tr><td rowspan="1" colspan="1">MF</td><td align="center" rowspan="1" colspan="1">4.42 &#x000b1; 0.89</td><td align="center" rowspan="1" colspan="1">11.39 &#x000b1; 1.07</td><td align="center" rowspan="1" colspan="1">25.82 &#x000b1; 1.24</td><td align="center" rowspan="1" colspan="1">35.79 &#x000b1; 0.98</td><td align="center" rowspan="1" colspan="1">43.39 &#x000b1; 1.17</td></tr><tr><td rowspan="1" colspan="1">SCR</td><td align="center" rowspan="1" colspan="1">4.10 &#x000b1; 0.91</td><td align="center" rowspan="1" colspan="1">11.25 &#x000b1; 1.07</td><td align="center" rowspan="1" colspan="1">25.58 &#x000b1; 1.07</td><td align="center" rowspan="1" colspan="1">35.64 &#x000b1; 0.91</td><td align="center" rowspan="1" colspan="1">43.48 &#x000b1; 1.00</td></tr></tbody></table><table-wrap-foot><fn><p> *<italic>P</italic> &#x0003c; .01 versus type 1 diabetes patients.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article> 